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Abstract 
Deficiency of adenosine deaminase (ADA, EC3.5.4.4), a housekeeping enzyme of purine 
metabolism encoded by the Ada gene, is a cause of human Severe Combined Immune Deficiency 
(SCID). Numerous deleterious mutations occurring in the ADA gene have been found in patients 
with profound lymphopenia (T- B- NK-), thus underscoring the importance of functional purine 
metabolism for the development of the immune defense. While untreated ADA SCID is a fatal 
disorder, there are multiple life-saving therapeutic modalities to restore ADA activity and 
reconstitute protective immunity, including enzyme replacement therapy (ERT), allogeneic 
hematopoietic stem cell transplantation (HSCT) and gene therapy (GT) with autologous gene-
corrected hematopoietic stem cells (HSC). We review the pathogenic mechanisms and clinical 
manifestations of ADA SCID.  
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Abbreviations 
ADA = adenosine deaminase 
Ado = adenosine 
AdoHCy = S-adenosyl-L-homocysteine 
BMT = bone marrow transplantation 
d-Ado = 2’-deoxyadenosine  
d-ATP = deoxyadenosine triphosphate 
DFSP = Dermatofibrosarcoma protuberans 
d-Ino = deoxyinosine 
dCydK = deoxycytidine kinase 
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ERT = enzyme replacement therapy 
GALT = gut-associated lymphoid tissue 
GI = Gastrointestinal 
HSCT = hematopoietic stem cell transplantation 
Ino = inosine 
PEG-ADA = polyethylene glycol conjugated adenosine deaminase 
PJP = Pneumocystis jiroveci pneumonia 
SCID = Severe Combined Immune Deficiency 
  
Introduction 
Severe combined immunodeficiency (SCID) arises from profound defects of immune system 
development and function and affected individuals are susceptible to severe and recurrent 
infections. The condition is genetically heterogeneous and to date approximately 20 different 
genetic causes have been identified.1 The identification of ADA deficiency as a cause of SCID 
occurred through serendipitous recognition of the absence of ADA enzyme from a few SCID 
patients, when ADA isozymes were being analyzed to compare compatibility among potential 
family donors and was the first form of SCID for which an underlying cause was determined.2 
ADA-deficiency accounts for 10-20% of human SCID, with an estimated incidence of ~1/500,000, 
based on a large population-based newborn screening ascertainment.3 ADA-deficient SCID is 
unique among the different genetic causes of human SCID in that it is not lymphocyte-specific, 
but rather a systemic purine metabolic disorder causing SCID and potentially extra-immune 
complications in the pulmonary, hematologic, GI, neurologic or skeletal systems.4   
     The pathophysiology connecting adenosine deaminase deficiency and SCID has been 
intensively studied (Table 1) and most of the mechanisms of the lymphotoxicity are understood 
(Figure 1) (Table 2). The mechanisms for the other manifestations of ADA deficiency are not fully 
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understood, although there are some insights, as discussed below. The development of a mouse 
model by ADA gene knock-out greatly increased understanding of pathogenic mechanisms and 
processes in the disease.  Fortunately, many of these manifestations are prevented by early 
restoration of ADA activity, by either ERT, allogeneic HSCT, or gene therapy. The management 
of ADA deficiency is not discussed in this review but is the subject of a recent review by the same 
authors.5  
 
Features of the Ada gene and enzyme 
Genetics 
The Ada gene was isolated in 1983 and is localized on the long arm of human chromosome 20 
(locus 20q13.11) and has been well characterized.6,7 It is 32 kb long and has 12 exons separated 
by 11 introns. The promoter region of the gene is 135 bases long, lacks the "TATA" and "CAAT" 
sequences usually present in eukaryotic promoters, and is extremely rich in G/C residues (82%).8 
It also contains three inverted repeats that allow the formation of cruciform structures, two direct 
repeats of 10 and 16 bp and five G/C-rich motifs (GGGCGGG) disposed in a strikingly symmetrical 
fashion.9 Northern blot analysis detected a major 1.6 kb mRNA transcript and a minor 5.8 kb 
transcript that may be a precursor of the mature 1.6 kb message.10 
 
A large number of mutations have been identified in children with ADA SCID.11 Studies expressing 
the defective ADA enzyme from known ADA SCID patient mutations in bacterial systems revealed 
that the genotype is an important determinant of enzymatic activity.12 The mutations could be 
categorized into those that resulted in i) single amino acid substitutions,13 ii) premature stop 
codons,14 iii) RNA splicing errors,15,16 iv) defects in post-translational modification of the ADA 
protein,17 and v) insertions or deletions2,18-20 of a DNA segment carrying the ADA gene. A number 
of specific mutations are seen more frequently in ADA patients and some of these are associated 
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with certain ethnic groups most probably as a result of a founder effect.21 In some cases, subtle 
changes in the configuration of the protein render the ADA enzyme unstable and/or catalytically 
inactive and thus prone to a rapid degradation.22-25 In other cases, the mutation was found in a 
regulatory region controlling expression of the ADA gene.26,27  
 
Molecular features 
The complete ADA amino acid sequence, deduced from cDNA and protein sequencing, consists 
of 363 amino acids, including the initiator Met. The enzyme consists of a single polypeptide chain 
with an estimated molecular weight of approximately 41 kDa, which contains carbohydrate and 
additional post-translational modifications.10,28  The ADA amino acid sequence is highly conserved 
from bacteria to humans.29 The sequences of human and murine ADA are ~83% identical,30 those 
of human and bovine ADA are ~93% identical.31 The homology between human and bovine ADA 
is of particular relevance since enzyme replacement therapy for ADA SCID is derived from bovine 
ADA.5  
 
Expression pattern  
The ADA enzyme has a large phylogenetic distribution and has been found in a wide variety of 
organisms, from microorganisms29,32 to plants,33 from invertebrate34 to vertebrate,35 from lower 
mammals31,36 to humans.37 In addition to expression in virtually all mammalian cells and tissues, 
ADA plays a unique and essential role in the differentiation and maturation of the immune system. 
ADA activity in the thymus is much higher than in any other organ.38 Intermediate ADA activity is 
observed in the GI tract, spleen, lymph nodes and skin while a low level of activity is observed in 
all non-lymphoid organs such as brain, liver and kidney.39 Among lymphocytes, ADA activity in 
cortical thymocytes is higher than that in medullary thymocytes and peripheral lymphocytes,40,41 
while activity in T cells is higher than that in B cells.42,43 ADA immunoreactive protein and 
translatable ADA mRNA were indeed found to be 6 to 8 times higher in T-lymphoblast lines than 
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in B-lymphoblast lines, which corresponded to increased ADA catalytic activity and protein in T 
cells compared to B cells.7 These observations suggest that fundamental differences in the rate 
of degradation of the ADA protein and in nucleotide metabolism may exist between T cells and B 
cells, and among members of the thymocyte lineage at various stages of maturation. The 
expression pattern of ADA highlights its importance in different organ systems and also why 
pathology in ADA SCID is not just confined to the immune system but also has severe systemic 
consequences in the brain and elsewhere. 
 
Researchers have demonstrated that ADA is not only a cytosolic enzyme, but it can be also found 
as an ecto-enzyme on the external side of the plasma membrane of hematopoietic cells,44 which 
suggests an obvious role of the enzyme in degrading extracellular adenosine to inosine.45 
However, ecto-ADA, which seems to be identical to intracellular ADA and has a globular structure, 
does not directly interact with membranes but rather with membrane proteins.46,47 So far, two 
types of surface anchoring proteins for ecto-ADA have been described. The first type, with only 
one member, is CD26 (dipeptidyl-peptidase IV, DPP4), a multifunctional protein of 110 kDa 
strongly expressed on epithelial and endothelial cells as well as fibroblasts and leukocytes.48 The 
second type of ecto-ADA-binding proteins includes the adenosine receptors (AR) A1 (A1R)49 and 
A2B (A2BR).50 The functional role of ecto-ADA/CD26 complex is still unclear, although CD26 was 
described as a proteolytic enzyme with a wide tissue distribution almost 30 years ago.51 However, 
it has been shown that ecto-ADA acts as a co-stimulatory molecule which facilitates a variety of 
specific signaling events in different cell types.52,53 The associated ecto-ADA/CD26 has been 
proposed to have a costimulatory function during T-cell receptor (TCR)/CD3 complex 
engagement54,55 and to mediate costimulatory signals in the immunological synapse leading to 
the stimulation of the T helper 1 (Th1) and pro-inflammatory cytokines IFN-γ, TNF-α, and IL-6.56 
A further role of ecto-ADA is to facilitate the signal transduction via A1R. Binding of ADA increases 
A1R affinity for the ligand, indicating that ADA is needed for an effective coupling between A1R 
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and heterotrimeric G proteins.49 Binding of ADA to A2BR regulates agonist binding to A2BRs by 
increasing the ligand-binding affinity and the 5’-N-ethylcarboxamidoadenosine (NECA)-induced 
second messenger production. Therefore, in lymphocytes, cell surface ADA, apart from degrading 
extracellular adenosine, regulates those actions of adenosine that are mediated via adenosine 
receptors of the A2B subtype.50 
 
Pathogenesis of ADA deficiency. 
Adenosine deaminase is a key enzyme of the purine-metabolism pathway which catalyzes the 
irreversible deamination of adenosine (Ado) and 2’-deoxyadenosine (d-Ado) into inosine (Ino) and 
2’-deoxyinosine (d-Ino), respectively.57,58 Adenosine and 2'-deoxyadenosine are purine 
nucleosides that are intermediates in the pathway of purine nucleotide degradation, and their 
turnover in cells involves a complicated series of regulated reactions.59 A number of disorders of 
purine metabolism have been shown to lead to immunodeficiencies.60  
 
In non-affected individuals, levels of purine nucleosides and deoxy-nucleosides in blood and urine 
are extremely low or undetectable. Alternatively, in patients with ADA SCID, marked elevation of 
both d-Ado and Ado in fluids and cellular components has been repeatedly noted and is 
considered the main cause of lymphotoxicity and other immunological and systemic 
pathologies.61,62 
 
Toxic effect caused by d-Ado build-up 
2’-Deoxyadenosine is a component of DNA and primarily derives from its degradation. Thus, 
lymphoid tissues such as the bone marrow and thymus, where lymphocytes undergo apoptosis 
during the maturation and differentiation process, are predisposed to generate and retain the 
highest amount of d-Ado.39,63 In the absence of ADA activity, d-Ado accumulates in extracellular 
compartments and within cells, where it is converted by the enzyme deoxycytidine kinase (dCydK) 
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to deoxyadenosine trisphosphate (d-ATP).64  Retained d-ATP has the potential to: i)  generate 
DNA strand breaks,65 ii) inhibit ribonucleotide reductase, an enzyme that participates in DNA 
synthesis and repair,66 iii)  induce apoptosis in developing thymocytes,67-69 and iv) interfere with 
terminal deoxynucleotidyl transferase (TdT) activity, thus limiting V(D)J recombination and 
antigen receptor diversity.70 Additionally, d-Ado irreversibly inactivates the enzyme S-adenosyl-L-
homocysteine hydrolase (SAHH) which catalyzes the reversible reaction: adenosine + L-
homocysteine ↔ S-adenosyl-L-homocysteine (AdoHCy). The SAHH inactivation prevents 
hydrolysis of AdoHCy, and as a consequence, its accumulation results in inhibition of 
transmethylation reactions necessary for effective lymphocyte activation.71-73 The cytotoxic build-
up of d-Ado, d-ATP and AdoHCy in lymphocytes is considered as the primary cause of 
lymphotoxicity. This is most apparent in the thymus where there is a very rate of thymocyte 
turnover during negative and positive selection and where the need for ADA expression is highest. 
The consequence of ADA deficiency and substrate accumulation is therefore to significantly 
disrupt thympoiesis so leading to the lymphopaenia seen in ADA deficiency. 
 
Toxic effect caused by Ado build-up  
Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar 
molecule moiety and Ado is a component of adenine nucleotides including ATP and RNA.74 ADA 
deficiency leads to both intracellular and extracellular accumulation of adenosine. Under normal 
physiological conditions, adenosine functions as an extracellular signaling molecule playing a role 
in fine-tuning the immune response via activation of plasma membrane G protein coupled 
receptors (GPCR) of target cells. However, this balanced regulation may be disrupted when 
adenosine concentrations are elevated, as in ADA deficiency.39,75 It has been shown that elevated 
levels of Ado may contribute to thymic apoptosis and inhibition of T-cell activation and expansion 
causing severe T lymphopenia in mice and humans.76,77 For example, activation of the A2A 
adenosine receptor by extracellular adenosine generates intracellular production of cAMP as a 
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consequence of tissue damage-associated deep hypoxia. Elevated levels of cAMP inhibit and 
trigger “off signaling pathways” in activated immune cells in a delayed negative feedback manner 
in order to prevent additional tissue damage.78,79 Apart from T-cell receptor signaling, adenosine 
is involved in the control of blood pressure and heart rate,80,81 renal function,82 pulmonary 
inflammation62,83,84 and in neurotransmission.85 
 
Clinical Manifestations.  
 
Immune deficiency. Many groups have previously reported the lymphocytotoxic effects of the 
accumulated adenine nucleotides, namely adenosine and deoxyadenosine, and their metabolites 
resulting in profound pan-lymphopenia (T, B and NK lymphocytes) in most ADA-deficient 
patients.86,87  Furthermore, these lymphocytes have been characterized by failed proliferation to 
mitogens, antigens, or allogeneic blood mononuclear cells.88 Patients with missense mutations 
and some minimal residual ADA enzyme activity may present at older ages (e.g. beyond one 
year) and have demonstrated less severe lymphopenia.89 In addition to impaired cellular 
immunity, ADA SCID patients have shown impaired humoral immunity as demonstrated by 
hypogammaglobulinemia and poor response to vaccination. Assessments in the murine model 
have shown absent germinal center formation, leading some groups to suggest that splenic 
dysfunction, previously noted via decreased mass and damaged structure in ADA SCID models, 
inhibits B-cell antigen dependent maturation.90 Indeed, live vaccines are contraindicated in this 
population, as with other immunodeficient groups, given the risk of reactivation and disseminated 
disease. Poliani et al. noted thymic atrophy and disrupted thymic architecture in tissue analysis 
of ADA SCID patients.91 ADA SCID patients have been noted to present with a spectrum of 
opportunistic infections, including Pneumocystis jiroveci pneumonia (PJP), candidiasis, otitis 
media, and other upper respiratory infections, atypical mycobacterium, herpes viruses and 
respiratory viruses, as well as live vaccination agents, including BCG, rotavirus, MMR, or 
varicella.92 
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Myeloid abnormalities. Features of myeloid dysplasia and bone marrow hypocellularity in ADA 
SCID have previously been reported.93 It has also been noted that prior to enzyme replacement 
therapy, absolute neutrophil counts were inversely proportional to plasma deoxynucleotide levels, 
suggesting that neutropenia occurs as a result of metabolic toxicity. In an analysis of 13 patients 
with active disease, the majority of the analyzed patients had hypogranular or vacuolated 
neutrophils and most had hyperlobular neutrophils. Of note, two cases demonstrated pseudo-
Pelger-Hüet neutrophils. Ubiquitously, atypical eosinophils were seen and characterized by 
cytoplasmic vacuoles, inconsistent granulation, or hyperlobular nuclei; these findings were 
independent of presence of absence of absolute eosinophilia.93 
Furthermore, patients with ADA SCID have demonstrated increased incidence of antibiotic-
induced myelotoxicity and prolonged neutropenia following nonmyeloablative chemotherapy.94 In 
one report, 3 of 4 patients undergoing gene therapy with low dose Busulfan preconditioning had 
prolonged neutropenia. Notably, these three patients also developed prolonged neutropenia 
following antibiotic therapy with trimethoprim-sulfamethoxazole, -lactam antibiotics and 
vancomycin.93 
Auto-immunity. An interesting phenomenon of auto-immunity has been described in patients 
with ADA SCID and recapitulated in some mouse models. Clinical manifestations of auto-
immunity may include autoimmune hypothyroidism, diabetes mellitus, hemolytic anemia, and 
immune thrombocytopenia seen in mild or late-onset forms of ADA SCID.95 Notably, classical 
forms of ADA SCID in humans and untreated ADA-/- mice do not develop clinical or laboratory 
features of autoimmunity, prior to treatment, perhaps because of the severe lymphopenia.96 
Cases of autoimmunity, including hemolytic anemia and thyroiditis have been reported in at least 
nine patients on long term polyethylene glycol conjugated adenosine deaminase (PEG-ADA) 
therapy.95 It has been postulated that PEG-ADA therapy interferes with Treg function via 
increased adenosine turnover due to abnormally high levels of ADA in the extracellular 
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environment and results in breakdown of tolerance. Treg generation of extracellular adenosine 
has previously been described as one of the mechanisms of Treg-mediated suppression of 
immune response, which maintains peripheral self-tolerance and prevents autoimmunity. 
Untreated ADA SCID mice showed excessively high extracellular adenosine concentrations, 
interfering with T-cell function, including that of Tregs, while excessive conversion of extracellular 
adenosine by PEG-ADA in treated mice appeared to block the Treg suppressor function.96 
Additionally, T-cell and B-cell receptor (TCR and BCR, respectively) signaling are critical in the 
development of a functional repertoire of immune cells in addition to destruction of auto-reactive 
cells. In the disease state, excessive extracellular adenosine increases intracellular cAMP which 
inhibits downstream intracellular signaling following TCR or BCR activation, resulting in 
attenuated response of the antigen-bound cell.95 Sauer et al. further posited that this 
downregulation of intracellular signaling could contribute to the survival of auto-reactive cells as 
the excessively strong TCR or BCR signals are dampened, when they would otherwise trigger 
apoptosis of the auto-reactive cell..95 ADA SCID patients who have undergone HSCT and gene 
therapy modalities have demonstrated development of physiologic levels and function of Tregs, 
although it is worth noting that autoimmunity has also been reported in these populations as 
well.97-99  
Neurodevelopment. Significant neurological or developmental problems have now been 
reported in several series of ADA SCID patients,100-102 although the exact frequency within the 
ADA deficient population is not known. Cognitive ability, as assessed by standard intelligence 
tests, was significantly lower in a group of ADA SCID patients with respect to age-matched 
controls, though it was not significantly lower than the group of non-ADA SCID controls who 
underwent prior BMT.100 Notably, there appeared to be an inverse correlation between 
deoxyadenosine triphosphate (dATP) levels at diagnosis and IQ.100 Additionally, behavior testing 
has demonstrated behavioral abnormalities in these patients that were statistically significant, with 
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respect to non-ADA SCID controls who received prior BMT100,102 as well as those treated with 
long term PEG-ADA replacement.102 Recent imaging data revealed white matter and ventricular 
changes on magnetic resonance imaging as well as EEG differences with respect to age 
controlled unaffected patients.102 Audiometric data has shown bilateral high-frequency 
sensorineural deafness in the majority of ADA SCID patients who underwent audiometric 
assessments post BMT. This hearing loss has been linked to the multisystem pathology of ADA 
SCID, rather than BMT conditioning regimens or ototoxic anti-infective medications given to 
assessed patients.102-104  
Mechanisms of CNS toxicity in ADA SCID are incompletely understood. Neurons or glial cells 
may be directly damaged by the metabolic abnormalities seen in ADA deficiency, or the 
pathologies may be secondary to insults, such as hypoxia related to pneumonia. Additionally, it 
is not known if the CNS defects develop in utero and are then static or if they progress postnatally. 
Normally, ADA expression is relatively high in the brain as previously measured, and it has been 
postulated that the absence of this enzyme results in an accumulation of dATP and resultant 
neuronal cell dysfunction in a similar manner to that seen in lymphocytes.100 Chick embryonal 
neurons studied in vitro and in vivo have provided further support for this hypothesis, by 
demonstrating sympathetic ganglia and optic tectum cell loss with inhibition of ADA. Interestingly, 
the severity of cell loss was dependent upon the embryonal stage of the chick, with inhibition of 
ADA earlier in the gestation resulting in greater volume loss, with the authors positing that the 
ADA inhibition resulted in halting cell proliferation.105 Because the degree, if any, of neuronal loss 
in the prenatal and postnatal periods is not known, it is difficult to determine whether early 
interventions, either ERT, HSCT, or gene therapy prevent or reverse them, although the clinical 
data suggests that these modalities do not result in improvement of neurological and audiological 
defects.100,101,103,104  
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Pulmonary. The accumulation of dATP has previously been shown in mouse models to cause 
pulmonary insufficiency and has been a major cause of mortality in these models.106,107 
Histologically, affected mice demonstrated accumulated activated alveolar macrophages and 
eosinophils, with abnormal alveolar formation. Furthermore, these histologic findings resolved 
with ERT.106   
Previous case reports of patients with ADA SCID have noted frequent occurrence of reactive 
airway diseases, even after successful treatment with ERT and BMT; these diseases include 
allergic rhinitis and asthma.107 Furthermore, eczema has also been reported in these cases, 
supporting a predilection toward atopy in affected patients.108 Extracellular adenosine is involved 
in purinergic signaling and modulates inflammation, and adenosine is elevated in bronchoalveolar 
lavage fluid from patients with asthma. Adenosine-inhalation in an allergic mouse model 
sensitized with ragweed, resulted in a dose-dependent bronchoconstriction. Bronchoalveolar 
lavage and tissue testing of these adenosine-treated mice demonstrated airway inflammation as 
shown by elevations of eosinophils, lymphocytes, and neutrophils, in addition to decreased 
macrophages.109 ADA SCID patients have a relative adenosine excess in the pulmonary system, 
which likely accounts for the increased incidence of reactive airway disease complications 
noted.110  
Booth et al examined cohorts of patients with ADA SCID and X-linked SCID with respiratory 
disease characterized by similar clinical and radiographic findings. They were able to isolate an 
infectious etiology significantly more frequently in the latter group, suggesting that lung pathology 
in ADA SCID may often be non-infectious. The non-infectious pulmonary disease found in patients 
with ADA SCID is thought to be due to metabolic injury, which is not seen in X-linked SCID.107 
Pulmonary Alveolar Proteinosis (PAP) represents a clinically significant non-infectious etiology of 
pulmonary disease in untreated ADA SCID patients.107,111  In these cases, patients exhibit 
hypoxemia, tachypnea, and infiltrates on chest X-ray.  Lung biopsies have been found to contain 
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proteinaceous material in the alveoli, and BAL fluid has shown abundant PAS+ foamy 
macrophages.  This clinical presentation is quite similar to that of PJP or other pneumonias, and 
these infectious causes need to be ruled-out to allow PAP to be attributed as the cause.  
Additionally, the rate of PAP recognized in patients with ADA SCID greatly exceeds that noted in 
patients with SCID from another mechanism.111 Notably, PAP was reversed with ERT or 
transplantation.111      
Gastrointestinal. Prior studies with untreated ADA deficient patients have demonstrated 
impaired development of gut-associated lymphoid tissue (GALT).112 Assessed patients did not 
have functional lymphoid cells and the Peyer’s patches lacked germinal centers.  
With regard to liver function, ADA deficient mice have severe hepatic abnormalities resulting in 
rapid hepatocellular degeneration, which proves fatal to them in the perinatal period.113 Although 
there are case reports of humans with ADA deficiency with hepatic pathology, by and large, 
patients with ADA SCID do not typically demonstrate clinically significant hepatic disease in early 
infancy or childhood, although they may have persistent mildly elevated liver enzymes on 
laboratory analysis.114   
Of note, with respect to overall intestinal motility in ADA SCID patients, there are reports of 
affected children with varying degrees of dysmotility and resultant challenges with feeding.115 ADA 
expression has previously been shown to be quite elevated in the gastrointestinal tract relative to 
other tissues.116 Taken together with the clinically significant gastrointestinal deficits observed in 
ADA-deficient patients, the finding of relative overexpression of ADA in the gut suggests that 
adenosine plays a fundamentally important role in the development and function of the 
gastrointestinal tract. Adenosine or its metabolites may act as an intestinal neurotransmitter or as 
a regulator of intestinal vasodilatation. In support of the latter possibility, a prior analysis of jejunal 
tissue undergoing absorption following suffusion with a nutrient solution showed hyperemia in the 
control versus treatment with ADA, suggesting that adenosine becomes elevated in response to 
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nutrients to cause vasodilation and this may be blunted by exogenous ADA. Additionally, these 
authors also demonstrated increased arteriolar diameter and resultant intestinal blood flow in a 
dose-dependent manner when treated with topical adenosine.117 ADA metabolizes adenosine to 
inosine, which has been established as a much weaker vasodilator relative to adenosine. Other 
disease processes with chronic intestinal vascular congestion, such as failing Fontan procedures 
or portal hypertension seen in hepatic failure, have well-established malabsorptive complications, 
including protein-losing enteropathy as well as fat and carbohydrate malabsorption. We speculate 
that abnormalities of adenosine in the congenital absence of ADA may play a role in the clinical 
symptoms of feeding intolerance, chronic diarrhea, and failure to thrive often seen in untreated 
ADA SCID infants. 
Skeletal. Children affected by ADA SCID have previously demonstrated a combination of unique 
skeletal abnormalities, especially prominent bulbous ends of the costochondral junctions (Rachitic 
Rosary) that may be seen on chest x-ray.118 They may have impaired linear growth by the time of 
diagnosis. Microscopic analysis of bones from patients with ADA who died without any treatment 
showed variable short growth plates with diminished numbers of functional chondrocytes.119 
Furthermore, the characteristic skeletal phenotype with altered structural and mechanical 
properties of bones in ADA gene knock-out mice has been linked to imbalance in the Receptor 
Activator of Nuclear Factor – ligand (RANKL)/osteoprotegerin axis that results in impaired 
osteoblast function and decreased osteoclastogenesis.120 Similar abnormalities of the RANKL 
pathway were observed in untreated ADA SCID patients.120  
Dermatologic. Dermatofibrosarcoma protuberans (DFSP) is a rare dermatologic soft tissue 
sarcoma seen with increased frequency in ADA SCID.121,122 The underlying chromosomal 
aberration is a translocation (t[17;22][q22;q13]), which produces a COL1A1-platelet-derived 
growth factor β (PDGFB) fusion gene.122 When associated with ADA SCID, DFSP has 
demonstrated specific features not characteristically seen in other presentations, including early 
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presentation and multicentricity. DFSP lesions were found in 8 of 12 patients by Kesserwan et al 
and were predominantly located on the trunk and extremities.122 The group posited that the 
characterized DNA repair defects in patients with ADA SCID resulted in the increased frequency 
of DFSP in this population.122 DFSP is slow growing with metastasis rates of <2% of cases.123 
Interestingly, there have been reports of DFSP occurrence and relapse of DFSP in ADA SCID 
patients following successful treatment with HSCT and PEG-ADA supplementation, suggesting 
that once formed in the ADA-deficient state, the DFSP may persist or progress even in an ADA 
replete environment. Given the predilection for this condition in treated and untreated ADA SCID, 
high clinical suspicion for the presence of DFSP and skin biopsy of suspicious lesions for 
diagnosis was propounded.122 The current standard of care has involved complete excision of the 
lesion, once diagnosed by skin biopsy, although these cases may become complicated by local 
relapses.124 
 
What has been learned from the mouse models of ADA SCID? 
In attempts to produce a murine model of ADA SCID, the Ada gene was knocked out in murine 
embryos; unexpectedly, the complete absence of ADA enzyme turned out to cause perinatal 
lethality, due to hepatoxicity.125,126 Similar severe liver problems are not seen in humans with two 
nonsense mutations of the Ada gene, indicating differences in the purine metabolic pathways in 
humans and mice. However, we have observed that ADA SCID patients, even after successful 
HSCT or gene therapy, may have persistently mildly elevated serum levels of hepatic 
transaminase enzymes, and this may be a mild form of the metabolic hepatotoxicity, although it 
does not seem to have significant clinical consequences.  
 
The same group of investigators had previously defined an enhancer element upstream of the 
murine Ada gene that directed expression of ADA in the placenta and trophoblast.127 Expression 
of ADA in these tissues of gestating murine mothers is critical to fetal survival, as evidenced by 
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the inability of Ada -/- female mice to bear Ada -/- pups after breeding with Ada +/- males 
(necessitating crosses of Ada +/- females with -/- males to produce litters with ~50% Ada -/- mice 
for studies)(personal observation). They then created a transgenic mouse using the 
placental/trophoblast enhancer to drive an Ada cDNA, leading to expression of ADA during 
gestation.128 Crossing the mice with the placental transgene with the Ada gene knock-out mice 
allowed the Ada -/- mice to survive beyond birth, but then be severely ADA-deficient post-natally.   
 
The neonatally-rescued Ada -/- mice were then observed to die in a highly consistent manner at 
three weeks of life.128 Death in these mice was due to pulmonary insufficiency, with profound 
airway inflammation seen, with enlarged and foamy macrophages and eosinophils, in the absence 
of detectable infection.106 This may be mechanistically similar to PAP that occurs commonly in 
human ADA SCID infants prior to treatment.111  Early institution of ADA enzyme replacement 
therapy, using the clinical-grade pegylated bovine ADA drug, was shown to rapidly rescue the 
mice from the pulmonary toxicity, essentially allowing normal murine life-span with chronic 
administration.110 Subsequently, other modes of ADA restoration were also shown to prevent the 
pulmonary complications, including congenic bone marrow transplants from ADA-replete 
donors,129 autologous bone marrow transplantation using retroviral130 or lentiviral vectors131 to 
stably introduce an Ada cDNA into the stem cells, or in vivo gene therapy by intravenous delivery 
of the Ada cDNA in lentiviral vectors.132  Adeno-associated virus (AAV) vectors have been used 
in a version of the Ada KO mouse in which foregut ADA expression prevents the lethal phenotype, 
although efficacy is hard to gauge in this mouse as there is partial immune reconstitution with 
foregut ADA expression. The in vivo route primarily delivers the Ada gene to the liver, which 
presumably acts as a metabolic sink to catabolize adenine nucleotides and achieve systemic 
detoxification and trans-rescue of lymphopoiesis.   
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Untreated Ada -/- mice have a SCID immunophenotype, when studied in the first weeks of life 
with severe pan-lymphopenia and profoundly reduced central lymphoid tissues.  However, any of 
the life-saving modes that restore ADA activity to prevent pulmonary death also lead to reversal 
of lymphopenia and the SCID immunophenotype. Unlike other forms of SCID with a cell intrinsic 
defect that provides an absolute dependence on gene correction for lymphocyte production, ADA-
deficiency may be improved by cross-correction of ADA-deficient cells by ADA expressed in other 
cells lowering system ADA substrate levels sufficiently to allow ADA-deficient lymphocytes to 
develop and survive. Neonatal Ada-/- mice transplanted with congenic ADA replete bone marrow 
showed donor lymphoid specific chimerism of 5%-10% but with normalization of immune cell 
numbers suggesting that a small number of ADA replete cells are able to ‘cross correct’ the 
system and allow recovery of endogenous defective ADA deficient cells.129   
 
Another important observation made in the ADA -/- mouse model is on the biodistribution of ADA 
ERT administered intramuscularly.110 The ADA was found essentially only in the plasma 
compartment and not in lymphoid tissues, such as thymus or spleen. The presence of high 
extracellular levels of ADA activity and low intracellular activity with ADA ERT may lead to 
consequences such as the predilection to auto-immune complications, as discussed (above) and 
incomplete correction of thymopoiesis and the sub-normal immune reconstitution that occurs in 
patients.   
 
The murine model has also helped elucidate a distinct neurophenotype present in ADA-deficient 
SCID. Specifically, mouse models demonstrated decreased activity and increased anxiety-like 
attributes. Subsequent biochemical studies by the researchers revealed consistent metabolic 
alterations and anomalous adenosine receptor signaling. Perhaps most notably, treatment with 
ADA replacement reversed metabolic perturbations, but did not influence the signaling 
abnormalities. The authors noted that PEG-ADA treatment did not increase ADA levels in the 
19 
 
brain, thought to be due to inability of medication passage through the blood-brain-barrier. 
Notably, there was a 10-fold decrease in brain levels of adenosine despite the absence of ADA 
in this tissue, which was attributed to peripheral ADA activity with total body decrement in 
adenosine levels, as adenosine and other metabolites diffuse readily across the blood-brain-
barrier.102 
 
Finally, the Ada gene knock-out mouse model has been used extensively to model clinical gene 
therapy approaches, to test efficacy and safety of approaches.131 There had been concern that 
ongoing ADA ERT at the time of a gene therapy procedure would diminish the extent of immune 
restoration, due to rescue of ADA-deficient cells blunting the putative selective advantage of ADA-
replete cells that would lead to reconstitution with gene-corrected cells. In fact, it was found that 
continuing ERT beyond the time of transplant of Ada -/- mice and for the first month after gene 
therapy did not prevent the development of a robust population of gene-corrected of T 
lymphocytes, which typically do not begin to emerge into the peripheral for several months after 
transplant.130 Based on these observations, some current clinical trials of gene therapy for ADA 
SCID are continuing ADA ERT for the first month beyond the transplant; this maintains 
lymphocytes that had developed under ERT during the peri-transplant period and minimizes the 
period of lymphopenia before de novo lymphopoiesis occurs from the gene-corrected graft. 
 
Conclusion 
ADA SCID is a multi-system disease with pathology extending well beyond the immune system. 
The lymphotoxicity caused by accumulation of deoxyadenosine has long been understood to 
underlie the severe immune deficiency in these patients, and more recently, complications with 
autoimmunity following initiation of treatment for the disease are coming to light. Intrinsic 
impairments in neurodevelopment are often exacerbated by long-hospital stays due to infection 
or malnutrition due to gastrointestinal pathology or infection. Early recognition of disease and 
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initiation of treatment can reverse this pathology, and we would encourage early involvement of 
a developmental specialist to promote language, motor, and social skills acquisition. Pulmonary 
structural pathology, namely PAP, independent of infection, has been a well-recognized 
complication of this disease and predilections toward reactive airway diseases and atopy are 
increasingly being recognized in this population. Hepatic pathology is inconsistently seen in this 
population and is much milder than that noted in mouse models. Gastrointestinal disease, widely 
noted in clinical settings, is incompletely understood at a molecular level. We propose that a 
constant relative adenosine excess at the intestinal level promotes vasodilation and hyperemia, 
creating diffuse vascular intestinal congestion and impairing nutrient absorption. This mechanism 
would be consistent with frequent reports of malnutrition, feeding intolerance, and reflux which 
are often seen in this population and incompletely accounted for by infection. Skeletal and skin 
manifestation of disease are also commonly involved, and practitioners caring for these children 
should have a high index of suspicion for potential linear growth impairment, impaired skeletal 
remodeling, and DFSP. Mouse models have been critical in our understanding of the multisystem 
pathologies encountered in this disease and in the development of current treatment modalities 
used in the clinical setting. 
 
ADA deficiency remains a complex and challenging condition. Our greater understanding of the 
mechanisms underlying the immunological defects has led in part to improved treatment options 
for this condition such as haematopoietic stem cell gene therapy. Our increased recognition of 
the multi-system defects may help drive further research that will allow better understanding and 
further management options. 
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Table 1.  Pathophysiology of Adenosine Deaminase (ADA)-Deficient SCID 
------------------------------------------------------------------------------------------------------------------------- 
Bi-allelic mutations in the adenosine deaminase (ADA) gene. 
Absence of adenosine deaminase enzyme (ADA). 
Adenosine and deoxyadenosine nucleosides not catabolized to inosine. 
Adenosine and deoxyadenosine accumulate systemically. 
Lymphocytes phosphorylate and trap the adenine nucleotides, esp. dATP.  
High levels of dATP are cytotoxic by multiple mechanisms causing death of T/B/NK 
lymphocytes. 
Pan-lymphopenia causes SCID, with opportunistic bacterial, viral and fungal infections possible. 
Systemic purine metabolic disorder may also affect liver, lungs, GI, and possibly CNS. 
 
------------------------------------------------------------------------------------------------------------------------- 
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Table 2. Mechanisms of lymphotoxicity in ADA SCID133  
------------------------------------------------------------------------------------------------------------------------- 
Thymus 
Widespread thymocyte apoptosis  
Abnormal thymocyte distribution with reduced CD4+CD8+ double-positive cells and increased 
double-negative cells 
Periphery, including lymph nodes, spleen, and circulating cells 
Accumulation of adenosine and 2’-deoxyadenosine, which are toxic to lymphocytes, through 
incompletely understood mechanisms, resulting in decreased peripheral survival of T, B, 
and NK cells 
Abnormal cell surface markers on T cells  
T cell receptor (TCR) activation defects resulting in defective activation and expansion 
Inhibition of TCR-induced signaling by adenosine 
Exacerbation of 2’-deoxyadenosine spontaneous and TCR-mediated apoptosis of lymphocytes 
Alterations in peripheral B cell distribution in spleen zones 
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Figure 1. Biochemstry of adenosine deaminase-deficient Severe Combined Immune Deficiency 
(ADA SCID). The nucleoside deoxyadenosine is deaminated by the enzyme adenosine 
deaminase (ADA) to produce deoxyinosine. Deoxyinosine may either be further catabolized down 
to uric acid, or may be salvaged for further use in purine metabolic pathways.  Lymphocytes 
especially have high levels of kinases which can successively phosphorylate deoxyadenosine to 
the nucleotides dAMP, dADP and dATP (collectively referred to as dAXP). dATP is the major 
metabolite that produces the pan-lymphotoxicity that leads to SCID.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
